Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation
Open Access
- 4 March 2021
- journal article
- retracted article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3), 330
- https://doi.org/10.3390/pharmaceutics13030330
Abstract
Genetic evidence has indicated that β-catenin plays a vital role in glucose and lipid metabolism. Here, we investigated whether pyrvinium, an anthelmintic agent previously reported as a down-regulator of cellular β-catenin levels, conferred any metabolic advantages in treatment of metabolic disorders. Glucose production and lipid accumulation were analyzed to assess metabolic response to pyrvinium in hepatocytes. The expression of key proteins and genes were assessed by immunoblotting and RT-PCR. The in vivo efficacy of pyrvinium against metabolic disorders was evaluated in the mice fed with a high fat diet (HFD). We found that pyrvinium inhibited glucose production and reduced lipogenesis by decreasing the expression of key genes in hepatocytes, which were partially elicited by the downregulation of β-catenin through AXIN stabilization. Interestingly, the AMPK pathway also played a role in the action of pyrvinium, dependent on AXIN stabilization but independent of β-catenin downregulation. In HFD-fed mice, pyrvinium treatment led to improvement in glucose tolerance, fatty liver disorder, and serum cholesterol levels along with a reduced body weight gain. Our results show that small molecule stabilization of AXIN using pyrvinium may lead to improved glucose and lipid metabolism, via β-catenin downregulation and AMPK activation.Funding Information
- National Science and Technology Major Project (2019ZX09201-002-006)
- U.S. Food and Drug Administration (2U01FD005946)
- Key Technologies Research and Development Program (2019YFE0190500)
This publication has 61 references indexed in Scilit:
- Lycium barbarum polysaccharides protect rat liver from non-alcoholic steatohepatitis-induced injuryNutrition & Diabetes, 2013
- Importance of β-Catenin in glucose and energy homeostasisScientific Reports, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Wnt Signaling Regulates Hepatic MetabolismScience Signaling, 2011
- Small-molecule inhibition of Wnt signaling through activation of casein kinase 1αNature Chemical Biology, 2010
- AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of β-catenin at Ser 552Biochemical and Biophysical Research Communications, 2010
- Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingNature, 2009
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association studyJournal of Medical Genetics, 2006
- Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetesNature Genetics, 2006